Bridgeway Capital Management’s TScan Therapeutics TCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $223K | Buy |
153,700
+40,400
| +36% | +$58.6K | 0.01% | 939 |
|
|
2025
Q1 | $156K | Buy |
113,300
+7,400
| +7% | +$10.2K | ﹤0.01% | 969 |
|
|
2024
Q4 | $322K | Buy |
105,900
+67,600
| +177% | +$206K | 0.01% | 907 |
|
|
2024
Q3 | $191K | Hold |
38,300
| – | – | ﹤0.01% | 1078 |
|
|
2024
Q2 | $224K | Sell |
38,300
-25,000
| -39% | -$146K | 0.01% | 1035 |
|
|
2024
Q1 | $503K | Sell |
63,300
-25,000
| -28% | -$199K | 0.01% | 925 |
|
|
2023
Q4 | $515K | Hold |
88,300
| – | – | 0.01% | 937 |
|
|
2023
Q3 | $226K | Buy |
88,300
+38,300
| +77% | +$98K | 0.01% | 1075 |
|
|
2023
Q2 | $125K | Sell |
50,000
-65,000
| -57% | -$163K | ﹤0.01% | 1222 |
|
|
2023
Q1 | $242K | Hold |
115,000
| – | – | 0.01% | 1067 |
|
|
2022
Q4 | $187K | Hold |
115,000
| – | – | ﹤0.01% | 1100 |
|
|
2022
Q3 | $351K | Hold |
115,000
| – | – | 0.01% | 990 |
|
|
2022
Q2 | $362K | Hold |
115,000
| – | – | 0.01% | 952 |
|
|
2022
Q1 | $322K | Buy |
115,000
+75,000
| +188% | +$210K | 0.01% | 1052 |
|
|
2021
Q4 | $180K | Buy |
+40,000
| New | +$180K | ﹤0.01% | 1173 |
|